Cargando…
Effects of rasagiline on Parkinson’s Disease Questionnaire (PDQ-39) emotional well-being domain in patients with Parkinson’s disease: A post-hoc analysis of clinical trials in Japan
BACKGROUND: Identifying the factors that influence health-related quality of life (HRQoL) is of great scientific interest, but a potential causal relationship between treatment and HRQoL has yet to be fully elucidated. Japanese patients reported better HRQoL outcomes on the Parkinson’s Disease Quest...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8789184/ https://www.ncbi.nlm.nih.gov/pubmed/35077474 http://dx.doi.org/10.1371/journal.pone.0262796 |
_version_ | 1784639712646922240 |
---|---|
author | Hattori, Nobutaka Takeda, Atsushi Hanya, Yuki Kitagawa, Tadayuki Arai, Masaki Furusawa, Yoshihiko Mochizuki, Hideki Nagai, Masahiro Takahashi, Ryosuke |
author_facet | Hattori, Nobutaka Takeda, Atsushi Hanya, Yuki Kitagawa, Tadayuki Arai, Masaki Furusawa, Yoshihiko Mochizuki, Hideki Nagai, Masahiro Takahashi, Ryosuke |
author_sort | Hattori, Nobutaka |
collection | PubMed |
description | BACKGROUND: Identifying the factors that influence health-related quality of life (HRQoL) is of great scientific interest, but a potential causal relationship between treatment and HRQoL has yet to be fully elucidated. Japanese patients reported better HRQoL outcomes on the Parkinson’s Disease Questionnaire (PDQ-39) emotional well-being domain, a 6-question subset of the PDQ-39 which is considered to reflect the emotional aspects of the disease-specific HRQoL, when treated with rasagiline, than placebo, in both a monotherapy clinical trial (NCT02337725) and an adjunctive therapy clinical trial in patients with wearing-off phenomena (NCT02337738). OBJECTIVE: To investigate how rasagiline exerts its effect on the PDQ-39 emotional well-being domain in Japanese patients with Parkinson’s disease. METHODS: A path analysis was performed to assess the direct treatment effects of rasagiline on the PDQ-39 emotional well-being domain and the effects mediated indirectly through the influence on items related to motor symptoms by a post-hoc analysis of two clinical trials in Japan. RESULTS: In the monotherapy trial, the PDQ-39 emotional well-being domain was mainly affected indirectly through items related to motor symptoms (80.7%) composed of the Movement Disorder Society-Unified Parkinson’s Disease Rating Scale (MDS-UPDRS) Part II (67.2%) and Part III (13.5%). In the adjunctive therapy trial, the PDQ-39 emotional well-being domain was also mainly influenced indirectly through effects on items related to motor symptoms (1 mg/day: 54.7%, 0.5 mg/day: 57.6%) composed of MDS-UPDRS Part II (1 mg/day: 35.6%, 0.5 mg/day: 40.9%), Part III (1 mg/day: 8.0%, 0.5 mg/day: 8.3%) and mean daily OFF-time (1 mg/day: 11.1%, 0.5 mg/day: 8.4%). CONCLUSIONS: The effects of rasagiline on the PDQ-39 emotional well-being domain were mediated primarily by influence on the subjective aspects of motor experiences of daily living. |
format | Online Article Text |
id | pubmed-8789184 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Public Library of Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-87891842022-01-26 Effects of rasagiline on Parkinson’s Disease Questionnaire (PDQ-39) emotional well-being domain in patients with Parkinson’s disease: A post-hoc analysis of clinical trials in Japan Hattori, Nobutaka Takeda, Atsushi Hanya, Yuki Kitagawa, Tadayuki Arai, Masaki Furusawa, Yoshihiko Mochizuki, Hideki Nagai, Masahiro Takahashi, Ryosuke PLoS One Research Article BACKGROUND: Identifying the factors that influence health-related quality of life (HRQoL) is of great scientific interest, but a potential causal relationship between treatment and HRQoL has yet to be fully elucidated. Japanese patients reported better HRQoL outcomes on the Parkinson’s Disease Questionnaire (PDQ-39) emotional well-being domain, a 6-question subset of the PDQ-39 which is considered to reflect the emotional aspects of the disease-specific HRQoL, when treated with rasagiline, than placebo, in both a monotherapy clinical trial (NCT02337725) and an adjunctive therapy clinical trial in patients with wearing-off phenomena (NCT02337738). OBJECTIVE: To investigate how rasagiline exerts its effect on the PDQ-39 emotional well-being domain in Japanese patients with Parkinson’s disease. METHODS: A path analysis was performed to assess the direct treatment effects of rasagiline on the PDQ-39 emotional well-being domain and the effects mediated indirectly through the influence on items related to motor symptoms by a post-hoc analysis of two clinical trials in Japan. RESULTS: In the monotherapy trial, the PDQ-39 emotional well-being domain was mainly affected indirectly through items related to motor symptoms (80.7%) composed of the Movement Disorder Society-Unified Parkinson’s Disease Rating Scale (MDS-UPDRS) Part II (67.2%) and Part III (13.5%). In the adjunctive therapy trial, the PDQ-39 emotional well-being domain was also mainly influenced indirectly through effects on items related to motor symptoms (1 mg/day: 54.7%, 0.5 mg/day: 57.6%) composed of MDS-UPDRS Part II (1 mg/day: 35.6%, 0.5 mg/day: 40.9%), Part III (1 mg/day: 8.0%, 0.5 mg/day: 8.3%) and mean daily OFF-time (1 mg/day: 11.1%, 0.5 mg/day: 8.4%). CONCLUSIONS: The effects of rasagiline on the PDQ-39 emotional well-being domain were mediated primarily by influence on the subjective aspects of motor experiences of daily living. Public Library of Science 2022-01-25 /pmc/articles/PMC8789184/ /pubmed/35077474 http://dx.doi.org/10.1371/journal.pone.0262796 Text en © 2022 Hattori et al https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
spellingShingle | Research Article Hattori, Nobutaka Takeda, Atsushi Hanya, Yuki Kitagawa, Tadayuki Arai, Masaki Furusawa, Yoshihiko Mochizuki, Hideki Nagai, Masahiro Takahashi, Ryosuke Effects of rasagiline on Parkinson’s Disease Questionnaire (PDQ-39) emotional well-being domain in patients with Parkinson’s disease: A post-hoc analysis of clinical trials in Japan |
title | Effects of rasagiline on Parkinson’s Disease Questionnaire (PDQ-39) emotional well-being domain in patients with Parkinson’s disease: A post-hoc analysis of clinical trials in Japan |
title_full | Effects of rasagiline on Parkinson’s Disease Questionnaire (PDQ-39) emotional well-being domain in patients with Parkinson’s disease: A post-hoc analysis of clinical trials in Japan |
title_fullStr | Effects of rasagiline on Parkinson’s Disease Questionnaire (PDQ-39) emotional well-being domain in patients with Parkinson’s disease: A post-hoc analysis of clinical trials in Japan |
title_full_unstemmed | Effects of rasagiline on Parkinson’s Disease Questionnaire (PDQ-39) emotional well-being domain in patients with Parkinson’s disease: A post-hoc analysis of clinical trials in Japan |
title_short | Effects of rasagiline on Parkinson’s Disease Questionnaire (PDQ-39) emotional well-being domain in patients with Parkinson’s disease: A post-hoc analysis of clinical trials in Japan |
title_sort | effects of rasagiline on parkinson’s disease questionnaire (pdq-39) emotional well-being domain in patients with parkinson’s disease: a post-hoc analysis of clinical trials in japan |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8789184/ https://www.ncbi.nlm.nih.gov/pubmed/35077474 http://dx.doi.org/10.1371/journal.pone.0262796 |
work_keys_str_mv | AT hattorinobutaka effectsofrasagilineonparkinsonsdiseasequestionnairepdq39emotionalwellbeingdomaininpatientswithparkinsonsdiseaseaposthocanalysisofclinicaltrialsinjapan AT takedaatsushi effectsofrasagilineonparkinsonsdiseasequestionnairepdq39emotionalwellbeingdomaininpatientswithparkinsonsdiseaseaposthocanalysisofclinicaltrialsinjapan AT hanyayuki effectsofrasagilineonparkinsonsdiseasequestionnairepdq39emotionalwellbeingdomaininpatientswithparkinsonsdiseaseaposthocanalysisofclinicaltrialsinjapan AT kitagawatadayuki effectsofrasagilineonparkinsonsdiseasequestionnairepdq39emotionalwellbeingdomaininpatientswithparkinsonsdiseaseaposthocanalysisofclinicaltrialsinjapan AT araimasaki effectsofrasagilineonparkinsonsdiseasequestionnairepdq39emotionalwellbeingdomaininpatientswithparkinsonsdiseaseaposthocanalysisofclinicaltrialsinjapan AT furusawayoshihiko effectsofrasagilineonparkinsonsdiseasequestionnairepdq39emotionalwellbeingdomaininpatientswithparkinsonsdiseaseaposthocanalysisofclinicaltrialsinjapan AT mochizukihideki effectsofrasagilineonparkinsonsdiseasequestionnairepdq39emotionalwellbeingdomaininpatientswithparkinsonsdiseaseaposthocanalysisofclinicaltrialsinjapan AT nagaimasahiro effectsofrasagilineonparkinsonsdiseasequestionnairepdq39emotionalwellbeingdomaininpatientswithparkinsonsdiseaseaposthocanalysisofclinicaltrialsinjapan AT takahashiryosuke effectsofrasagilineonparkinsonsdiseasequestionnairepdq39emotionalwellbeingdomaininpatientswithparkinsonsdiseaseaposthocanalysisofclinicaltrialsinjapan |